Oxygen is an essential medicine for life-threatening hypoxemic illnesses, including pneumonia, which is currently the leading cause of childhood mortality worldwide.
cal trial of solar-powered oxygen delivery vs standard oxygen delivery using compressed oxygen cylinders among children younger than 13 years with hypoxemic illness at 2 resourceconstrained hospitals in Uganda. The trial protocol and methods have previously been published 6 (trial protocol in the Supplement) and the trial was registered (clinicaltrials.gov NCT02100865). The trial was designed to demonstrate noninferiority of solar-powered oxygen delivery relative to oxygen cylinders, using a clinically meaningful end point, length of hospital stay, expressed as a continuous variable using the date and hour of admission and discharge, using a noninferiority margin of 1 day. [22] months) were enrolled between March 29, 2014 , and May 13, 2015 ; of these, 65 (50.0%) were assigned to solar-powered oxygen delivery and 65 to cylinder oxygen. Baseline characteristics were similar between groups (Table) . The median length of hospital stay was
Author Audio Interview Supplemental content b Respiratory rate greater than 99th percentile for age.
c Pulse rate greater than 99th percentile for age.
d Axillary temperature greater than 37.5°C.
e All children were tested for malaria using rapid diagnostic test (histidine-rich protein-2 antigen) and/or light microscopy of Field-stained peripheral blood film.
4.1 days (interquartile range, 2.9-5.6 days) in the solarpowered oxygen delivery group and 4.5 days (interquartile range, 3.3-6.9 days) in the cylinder oxygen group; the difference of medians was -0.41 days (95% CI, -1.2 to 0.43), meeting the prespecified criterion for noninferiority. In-hospital mortality was similar between groups: 11 patients (17%) in the solar-powered oxygen delivery group vs 8 patients (12%) in the cylinder oxygen group (risk difference, 4.6%; 95% CI, -7.8% to 17%). In a competing risk analysis with in-hospital mortality and hospital discharge as competing events, the time to discharge and mortality were not statistically different between groups (Figure, A) . The increase in peripheral blood oxygen saturation (Figure, B) , and the time to wean off oxygen were similar (Figure, C). Adverse events were similar in both groups. Five episodes of battery depletion involving 7 patients required recharging the batteries of the solar-powered oxygen system using the hydroelectric grid or switching patients to the backup oxygen supply. Conversely, 4 patients randomized to receive cylinder oxygen were switched to the backup oxygen supply when cylinders stocks were depleted, despite our best efforts to maintain adequate stocks of cylinders.
Discussion | Solar-powered oxygen delivery is noninferior to standard oxygen delivery using cylinders among African children hospitalized with hypoxemic illness. This technological innovation may be suitable for low-resource hospitals with pediatric inpatient services where the supply chain of cylinders and electrical power are not reliable. Solar-powered oxygen delivery addresses a critical gap in access to oxygen and has the potential for global consequences, given the magnitude of childhood pneumonia deaths, currently estimated at 900 000 per year. A, Mortality and time to hospital discharge among trial participants. Mortality (orange lines) and hospital discharge (blue lines) in the solar-powered oxygen delivery group (solid lines) and cylinder oxygen comparator group (dashed lines) are modeled as competing risks. Differences between treatment arms were not statistically significantly different for mortality or time to hospital discharge. B, Rapid resolution of hypoxemia among trial participants. Immediate improvements in oxygen saturation were observed in both trial arms after administration of oxygen therapy, with no difference between patients receiving solar-powered oxygen (median change, 15% [interquartile range, 12%-21%]) and cylinder oxygen (median change, 15% [interquartile range, 11%-23%]). C, Time to wean off oxygen among trial participants. The median duration of oxygen therapy was similar in patients receiving solar-powered oxygen (2.6 days [interquartile range, 1.6-4.0 days]) and cylinder oxygen (2.1 days [interquartile range, 1.7-4.9 days]). A standardized protocol for stopping oxygen therapy was observed.
Incidence of 4 Lysosomal Storage Disorders From 4 Years of Newborn Screening
Newborn screening is recognized as a highly effective public health program to detect certain diseases before detrimental longterm health consequences occur. With advances in screening technologies and therapeutic options becoming available, the US Department of Health and Human Services recently added 2 lysosomal storage disorders (LSDs), Pompe disease and mucopolysaccharidosis I (MPS I), to the Recommended Uniform Screening Panel. 1 In addition, several states have legislative mandates to screen for other LSDs not on the Recommended Uniform Screening Panel. The Missouri State Public Health Laboratory has used a fluorimetric enzyme activity test on a digital microfluidic platform to screen all samples from newborns that were received since January 11, 2013, for Pompe, MPS I, Gaucher, and Fabry disorders. 2 We herein present our findings on incidence rates for these LSDs from 4 years of full-population testing. These results represent, to our knowledge, the longest prospective, unblinded, full-population testing and follow-up for these LSDs in the United States.
Methods | Enzyme activity for acid α-glucosidase deficiency (Pompe disease), acid α-galactosidase deficiency (Fabry disease), acid β-glucocerebrosidase deficiency (Gaucher disease), and acid α-L-iduronidase deficiency (MPS I) was measured from dried blood spots using a fluorescence enzyme assay on the digital microfluidic platform (Baebies, Inc) as previously described. 
OBJECTIVE
The objective of this proposal is demonstrate that solar energy can be used to concentrate oxygen from ambient air to improve peripheral blood oxygenation in children hospitalized with acute hypoxic respiratory illness in resource-constrained sub-Saharan African settings.
Our specific aims are: 1. Implement solar oxygen system and collect operational data  To install and monitor the functioning and costs of a solar-driven oxygen concentrator system at a resource-constrained pediatric centre in subSaharan Africa.  To generate operational data for future scale-up of solar-powered oxygen concentrator system: (a) quantify power requirements of the oxygen concentrator for individual pediatric patients with hypoxic respiratory illness; (b) quantify power provided by solar panels in an operational setting in sub-Saharan Africa.  To demonstrate that patients with hypoxic respiratory illness receiving oxygen by solar-powered oxygen concentrators have improved peripheral blood saturation.  To measure serum biomarkers of critical pathways of host defense to infection and hypoxia longitudinally over the course of hospitalization among children with hypoxic respiratory illness.
Examine efficacy and cost-effectiveness of solar oxygen delivery relative to
conventional oxygen delivery  To compare a solar powered oxygen concentrator system to conventional oxygen delivery system (oxygen in pressurized cylinders) in terms of clinical efficacy, cost-effectiveness, and feasibility.  To equip and augment a pneumonia mortality surveillance system at 6 acute care centres across Uganda.  To implement solar powered oxygen at 3 intervention sites, comparing pneumonia outcomes at intervention and control sites.
The working hypothesis is that solar energy can be used to drive oxygen concentrators to improve outcomes in pediatric patients with hypoxic respiratory illness. This will be assessed in terms of feasibility in a first proof-of-concept stage at a single pediatric centre. The technology will then be compared to conventional
Introduction
Globally, approximately 7.7 million children per year die before the age of 5 years.
Infectious diseases account for a large proportion of these deaths, with pneumonia being the leading cause of mortality (2.1 million deaths/year) 1 . Most deaths occur in resource-poor settings in Africa and Asia 2 . Countries in Africa and Asia report 2 to 10 times more children with pneumonia (7 to 40/100 annually) than industrialized countries like the USA 3 . In Uganda alone, child mortality is estimated to be 145,000 deaths per year. Bacterial pneumonia, tuberculosis, sepsis and severe malaria are common infectious etiologies; all of which lead to respiratory distress as a final common pathway. Oxygen (O 2 ) therapy is essential to support life in these patients. Large gaps remain in the case management of children presenting to African hospitals with respiratory distress, including essential supportive therapies such as supplemental oxygen. In resource-constrained settings, oxygen delivery systems can lead to measurable improvements in survival from childhood pneumonia. A multihospital effectiveness study in Papua New Guinea demonstrated a reduction in mortality from childhood pneumonia from 5.0% to 3.2% (35% reduction in mortality) after implementation of enhanced oxygen delivery system 4 . We propose to investigate a novel strategy for oxygen delivery that could be implemented in remote locations with minimal access to an electrical power supply: solar-powered oxygen (SPO2).
Literature Review
The World Health Organization (WHO) Integrated Management of Childhood Illnesses (IMCI) provides a classification of pneumonia based on clinical features, differentiating 3 risk strata: (1) cough and cold; (2) pneumonia; (3) severe pneumonia or very severe disease 5 .
Clinical features of pneumonia in children include fever, respiratory distress, and hypoxemia. Respiratory distress is a useful clinical summary description with good inter-observer consistency among experienced medical practitioners 6 . Kussmaul breathing). Respiratory distress is a sign that one or more serious pathological processes are at play: metabolic acidosis, fluid overload, acute lung injury, and/or co-morbid pneumonitis. Respiratory distress, together with alteration of consciousness, is a strong predictor of mortality in children with severe febrile illness in sub-Saharan Africa 7 . The grim prognostic significance of respiratory distress applies to several disease states, irrespective of microbial etiology, including malaria as well as non-malaria febrile illness 7 .
Arterial hypoxemia in pneumonia results from several mechanisms: pulmonary arterial blood flow to consolidated lung resulting in an intrapulmonary shunt, intrapulmonary oxygen consumption, and ventilation-perfusion mismatch 8 .
Hypoxemia is a risk factor for mortality in pediatric pneumonia, and was associated with a 5-fold increased risk of death in studies from Kenya and Gambia 9 .
In one report from Nepal, the prevalence of hypoxemia (SpO2 < 90%) in 150 children with pneumonia was 39% overall, with increasing rates of hypoxemia across strata of pneumonia severity (100% of very severe, 80% of severe and 17% of pneumonia patients) 10 . General features of respiratory distress were associated with hypoxemia in this study, including chest indrawing, lethargy, grunting, nasal flaring, cyanosis, inability to breastfeed or drink.
Few studies have reported on the use of solar powered oxygen delivery. One online report describes the use of a battery-powered oxygenator in the Gambia that could be adapted to use solar power (http://www.dulas.org.uk). Otherwise, our intervention is to our knowledge the first example of solar powered oxygen delivery.
Among the etiologies of respiratory distress in patients presenting to hospital in subSaharan Africa, viral respiratory tract infection, bacterial pneumonia, severe malaria and tuberculosis are important considerations. Viral bronchiolitis is a prevalent respiratory illness among infants and young children. Severe malaria represents another common cause of respiratory distress in the subSaharan context. Malaria is the most common diagnosis among hospitalized children in Africa 7 and is associated with a mortality of 10-30%, even with highly effective anti-parasitic medications 11 . In sub-Saharan Africa, cohort studies indicate that 17-29% of patients with severe malaria presenting to hospital emergency facilities have respiratory distress 12 . The presence of deep breathing, characterized by increased inspiratory and expiratory excursion of the chest is generally associated with metabolic acidosis and portends a high mortality 6, 13 . The pathophysiology of respiratory distress in malaria may involve one or more mechanisms, including non-cardiogenic pulmonary edema and acidosis. Pulmonary edema is a well recognized complication of malaria in adults 14 , but appears to be less common in children. In children hospitalized with malaria in sub-Saharan Africa, metabolic acidosis and hypovolemia are common presenting signs 15 .
Echocardiography reveals severe tachycardia, low stroke volume index, and high inferior vena cava collapsibility index 16 . Thus, impaired tissue perfusion, metabolic acidosis, and Kussmaul breathing, representing an acute pulmonary compensation to systemic metabolic acidosis, appear to account for most cases of respiratory distress in children. Of note, lactic acidosis is a prognostic marker for mortality in children with severe malaria 17 , and its association with respiratory distress ___________________________________________________________________ Version 3: 15 Oct, 2013 7
represents a final common pathway of decompensated shock, cardiopulmonary insufficiency and impending death. Furthermore, hypoxia related to pulmonary involvement may itself provoke convulsions and deterioration in the level of consciousness and may be the immediate precipitant of death.
Host response to pneumonia
In addition to examining solar-powered oxygen concentrators as a novel oxygen delivery system, we propose to investigate host response in the context of hypoxic respiratory illness. The following literature review focuses on pathways of host response to pneumonia and its causative pathogens.
Inflammation
Excessive pro-inflammatory responses to infection are observed in severe infections such as malaria, pneumonia, and sepsis 18 . The acute-phase reactants C-reactive protein (CRP) and procalcitonin (PCT) are elevated in the setting of bacterial infection 19 . These markers have been used in clinical practice to distinguish between severe bacterial infection and benign causes of fever in children. Other potentially informative inflammatory markers include the 10 kDa interferon gammainduced protein (IP-10), a chemokine elevated in fatal malaria 20 , and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1). The triggering receptor expressed on myeloid cells-1 (TREM-1) mediates pro-inflammatory responses 21 .
Inhibition of TREM-1 improves outcome in murine models of sepsis 22 . Membrane density of TREM-1 on peripheral monocytes appears to be increased in patients with uncomplicated malaria cases compared to uninfected individuals 23 . Soluble TREM-1 (sTREM-1) is generated by cleavage of membrane TREM-1 upon myeloid cell activation 24 , thereby serving as peripheral blood marker of leucocyte stimulation.
Both membrane and sTREM-1 are increased in inflammatory pathologies in humans 25 . We will assess these host proteins among children hospitalized for hypoxic respiratory failure to assess their potential role in pathogenesis.
Endothelial activation
Widespread endothelial activation with capillary leak leads to multi-system organ failure in severe sepsis 26 and malaria 27 . Endothelial activation in the pulmonary vasculature may account in part for impaired gas exchange and hypoxemia in pediatric pneumonia. Following activation by pro-inflammatory stimuli, soluble endothelial cell receptors are released into the circulation via ectodomain shedding or alternative splicing, such that peripheral blood levels of key regulatory proteins reflect the state of whole body endothelial activation. We will examine several critical molecules involved in the regulation of endothelial quiescence and activation. 28, 29 . Likewise, the cell surface receptor Pselectin may be shed from the endothelium in severe disease. We hypothesize that elevated levels of sICAM-1 and/or sP-selectin may also predict adverse outcomes in hospitalized African children.
___________________________________________________________________
Soluble FMS-like tyrosine kinase-1 (sFlt-1) is generated by alternative splicing of VEGF receptor-1 mRNA and antagonizes the pro-inflammatory and pro-angiogenic effects of VEGF. sFlt-1 is elevated in children with severe malaria as well as sepsis patients 30 . Data from murine models of sepsis suggest that sFlt-1 may play a modulatory role 31 , counteracting increased VEGF tissue expression and plasma levels, associated with cerebral malaria 32 . Similarly, endoglin, a component of the tumor necrosis factor-beta (TGF-) receptor complex, participates in inflammatory signaling pathways. The soluble form of the receptor (s-endoglin) is shed from the endothelial surface into the circulation in the setting of critical illness. We hypothesize that sFlt-1 and/or s-endoglin may be clinically informative markers of disease severity in hospitalized African children.
Angiopoietins (Angs) represent a distinct family of vascular growth factors that are increasingly recognized for their role in infectious disease pathogenesis. Four molecules have been characterized, Ang-1, Ang-2, Ang-3, and Ang-4, which signal through the Tie-2 receptor on endothelial cells. Ang-1 is secreted from pericytes within the vascular intima, whereas Ang-2 is stored with von Willebrand factor in Wiebel-Palade bodies. Ang-1 and Ang-2 act antagonistically: Ang-1 promotes stability of the vascular endothelium and Ang-2 promotes permeability of the bloodtissue barrier 26, 33 . Ang-2 also functions as an autocrine regulator by sensitizing the endothelium to the effects of TNF, resulting in increased adhesion receptor expression 34 . Like other endothelial surface molecules, the Tie-2 receptor is released into the circulation in severe illness. Our group has previously described the clinical utility of peripheral blood angiopoietins and sTie-2 for prognosis in sepsis 26 and malaria 27, 35, 36 . We hypothesize that their clinical utility may also be extended to common childhood illnesses requiring hospital admission.
Coagulation
Coagulopathy is a well-recognized manifestation of several severe infectious syndromes such as meningococcemia, sepsis and severe malaria. In addition, regulation of the coagulation cascade is intimately linked to the vascular endothelium, such that alterations in the profile of coagulation proteins also reflect activation and/or dysfunction of the endothelium. Like Ang-2, vWF and its precursor, ___________________________________________________________________ Version 3: 15 Oct, 2013 9 vWF propeptide, are stored within WP bodies and released into the circulation in response to inflammatory stimuli. We plan to evaluate vWF and its precursor, vWF propeptide, as potential markers of severe disease in hospitalized African children.
METHODOLOGY
A. Proof-of-concept and operational data This phase of the project will involve the installation and monitoring of a SPO2 system at Jinja Regional Referral Hospital, Uganda. An existing 4-bed intensive care unit will be refurbished to accommodate a stand-alone "off-the-grid" solar electricity system and an oxygen concentrator capable of delivering up to 10L/min of O 2 to 2 patients simultaneously. The unit also has the capacity to deliver O 2 by cylinder as a failsafe mechanism, and has backup electrical supply including a generator, battery and inverter system.
The electrical specifications of the system (power generated by solar panels and power consumed by oxygen concentrator) will be measured in order to inform prototype design and future scale-up of the technology. Daily and seasonal variations in solar power will be of particular interest in this descriptive phase of the study.
Patients with hypoxic respiratory failure will approached for consent to participate in the study and we will monitor the peripheral blood oxygen saturation before and after administration of supplemental SPO2 among consenting subjects. This phase of the study will be descriptive (case series) in order to demonstrate the clinical efficacy of solar-powered oxygen.
B. Comparison to standard oxygen-delivery sytem: compressed oxygen
cylinders Randomized prospective controlled study. In order to compare the new oxygen delivery system to a conventional method (oxygen in compressed cylinders), we will prospectively enroll children with hypoxic respiratory illness. Children will be randomly assigned to receive oxygen using either solar-powered oxygen or oxygen from compressed air cylinders in a 1:1 ratio. Enrolment will occur at 2 sites: Jinja Regional Referral Hospital and Kambuga District Hospital.
The a priori hypothesis is that solar-powered oxygen will be non-inferior to a conventional oxygen delivery system in terms of a clinically meaningful outcome: length of hospital stay.
___________________________________________________________________

Version 3: 15 Oct, 2013 10
Secondary study endpoints will be: mortality, duration of supplemental oxygen therapy (time to wean O 2 ), proportion of patients successfully oxygenated, delivery system failure, cost, system maintenance and convenience.
C. Microbial etiology and biomarkers and critical illness pathways in pediatric pneumonia
Samples obtained in the course of admission may be analysed for evidence of bacterial and viral pathogens. Nasal swabs may be collected at admission for storage and subsequent analysis for viral pathogens. Peripheral blood samples may be analysed using molecular techniques for Streptococcus pneumoniae, a common and vaccine-preventable bacterial etiology of childhood pneumonia.
As an additional element of this prospective study, we propose to examine peripheral blood biomarkers of host response to infection and genetic factors, in order to gain insights into pneumonia pathogenesis. This aspect of the study aims to examine activation of critical illness pathways (inflammation, angiogenesis, coagulation and endothelial stability) in pediatric hypoxemic pneumonia over the time course of hospital admission. This will be achieved using several selected peripheral blood proteins, alone and in combination, as quantitative biomarkers of critical pathobiological pathways.
Our prospective study will longitudinally follow peripheral blood levels of key host biomarkers of inflammation, hypoxia, angiogenesis, coagulation and endothelial stability in patients hospitalized with hypoxic respiratory illness. This will yield rich insights into biological pathways activated in disease and their kinetics during recovery from illness. Furthermore, we will link information about clinical outcomes (i.e., mortality and length of admission) to quantitative biomarker levels and their dynamic profile over the course of hospitalization. This information may demonstrate the clinical utility of these biomarkers for patient triage, diagnosis and assignment to advanced therapeutics. Our findings may accelerate the development of new tools for case management that can assist practitioners in resource-constrained African hospitals providing health care to children with hypoxic respiratory illness. New tools for clinical care, in turn, may save lives in resource-constrained settings by focusing efforts toward improved child survival.
Protein biomarkers will be measured using commercially-available enzyme-linked immunosorbent assays (ELISA). Testing for genetic markers of host response to infection may involve micro-array and/or deep sequencing techniques. Relevant biomarkers from critical illness pathways will include the following (although 
Biomarkers of coagulation  von Willebrand Factor (vWF)  vWF propeptide
Biomarkers of angiogenesis and endothelial stability
D. Multi-centre prospective evaluation of solar-powered oxygen This phase of the study will involve roll out of SPO2 delivery systems to intervention sites across Uganda, with a comparison to control sites without SPO2. An inpatient mortality surveillance system is already in place across 6 sentinel sites in Uganda (led by co-investigator Dr. Mpimbaza). The first step will be to augment the capacity of the surveillance sites for pulse oximetry and data capture of key parameters of pneumonia (e.g., respiratory rate). Once the pneumonia mortality surveillance system is operational at all 6 sites and baseline mortality data has been collected, we will implement SPO2 systems at 3 of the 6 sites (intervention sites) and prospectively monitor pneumonia-specific mortality rates at both intervention and control sites. The hypothesis is that introduction of SPO2 systems will result in a lower pneumonia-specific mortality rate at intervention sites, whereas minimal change in the mortality rate will be observed at the control sites. The analysis will be based on a comparison of change (before-after) in pneumonia-specific mortality at intervention sites versus control sites. In the interest of equity, control sites may be offered solar oxygen delivery systems at the end of the data collection period. 50 . These scoring systems, unlike LODS, make use of laboratory parameters to derive a total prognostic score, which are not available in our resource-limited hospital, as elsewhere in other African settings where child mortality is highest 51 .
___________________________________________________________________
Sample size
We will enroll a total of 130 hospitalized patients. The primary endpoint is length of stay and the hypothesis tested for the primary analysis is that SPO2 is not inferior to standard oxygen delivery (compressed air cylinders).
This sample size was calculated as follows. A 1:1 ratio of patients will be assigned to SPO2 or control (O 2 from cylinders). We consider a 1 day prolongation of hospital stay to be clinically significant (non-inferiority margin). Using pilot data from a prospective study at Jinja Regional Referral Hospital, 69 patients with hypoxic pneumonia had a mean (standard deviation) length of stay of 2.6 (2.1) days. By standard calculations for normally distributed data, 57 patients in each group will provide 80% power to demonstrate non-inferiority of SPO2 relative to oxygen by cylinder. This sample size was increased by 15% to account for probable nonGaussian distribution of the data 52 .
Statistical Considerations
Primary outcome Length of stay will be coded as a whole number (continuous variable). Nonparametric tests (Mann-Whitney) will be used to compare the length of stay between groups. The level of significance will be =0.05. The hypothesis test is framed as follows: H 0 : the length of stay among patients treated with SPO2 is greater than the length of stay among patients treated with oxygen by compressed air cylinder. The alternative hypothesis, that SPO2 delivery in non-inferior, will be accepted (power=80%) if p>0.05 (one-sided), or if the length of stay is significantly shorter in the SPO2 group. ___________________________________________________________________ Version 3: 15 Oct, 2013 14
Secondary outcomes
The mortality will be compared between groups using the chi-squared statistic, or Fisher's exact test, as appropriate. Proportion of patients successfully oxygenated and proportion of patients for whom the oxygen delivery system failed will be analysed in a similar manner. The duration of oxygen therapy will be compared using non-parametric methods (Mann-Whitney U-test) and/or Cox-proportional hazard models. Costs will be carefully tabulated (capital investment, ongoing costs, system maintenance, etc.) and summarized for each group of patients. Details of maintenance needs and convenience of use of the systems will be documented and tabulated. The LODS (clinical severity score) will be assessed and recorded serially over the course of hospital admission; comparison between groups will make use of mixed effects linear models to compare the longitudinal time course of recovery in the clinical severity score.
Biomarkers of host response to infection will be measured serially throughout the course of hospital admission. Quantitative peripheral blood levels of these biomarkers with be compared using mixed-effects linear models to compare the longitudinal time course of the change in biomarker levels.
Study Procedures
For pediatric patients presenting to Jinja Regional Referral Hospital in whom admission to hospital is deemed necessary by an attending physician, the parent or guardian will be approached for consent to participate in the study. If granted, the patient will be transferred to a dedicated pneumonia ward, where the patient will be randomized to receive oxygen with the SPO2 system, or with oxygen cylinders (control group). All patients will receive standard care for their underlying disease, including antibiotics for pneumonia, intravenous fluids as necessary, blood transfusion as necessary, antipyretics, and any other medical therapy required. A small volume (1mL) of blood will be withdrawn for processing and storage at admission and daily during the course of hospitalization. A RDT for malaria will be tested at admission, and whole blood lactate level will be performed at the bedside for each of the daily blood draws. Basic demographic and clinical data will be collected from the case admission record, and patients will be followed during their hospital admission. Possible outcomes will include: death, discharge without disability, discharge with disability, abscondment, and loss to follow-up. The length of stay among survivors will be recorded. Serum samples will be shipped to the collaborating laboratory in Canada for analysis for biomarkers. ELISA-based commercially-available assays for biomarker levels will be used to quantify biomarker levels. In order to measure levels of 13 biomarkers ___________________________________________________________________ Version 3: 15 Oct, 2013 15 from a plasma sample of 500uL or less, highly co-ordinated procedures with experienced technicians are required to perform the ELISA. Our laboratory in Canada has established protocols, experienced staff able to perform the testing, as well as equipment and reagents allowing the testing to be done efficiently. While it would be desirable to augment Ugandan capacity for biomarker testing, this would require significant investment of time and resources for training and testing, and may not be feasible in the context of this early study. If biomarkers can be identified that have clinical utility, laboratory capacity for ELISA measurement of levels should be developed or a simplified platform (e.g., lateral flow immunochromatographic test) should be developed.
Pneumonia will be diagnosed clinically, on the basis of WHO (IMCI) criteria. A combination of tachypnea, respiratory distress (nasal flaring, intercostal and/or subcostal indrawing, or cyanosis) and characteristic findings on chest auscultation (asymmetrical air entry, crackles, dullness to percussion) will be used to make a clinical diagnosis of pneumonia. In our setting, chest x-ray is not available on site and radiographic confirmation will not be routinely available.
Safety monitoring
Adverse events will be monitored by study staff and recorded on a log. The relatedness to the study intervention (oxygen) and the severity of the adverse event will be judged by the study personnel. Serious adverse events, defined as those which lead to death, permanent disability, or that prolong hospitalization will be reported in an expedited manner to the SOBSREC and to the UNCST. Other adverse events will be tabulated and presented in an annual report and/or final report. Patients with adverse events will be managed according to Uganda National Guidelines.
Limitations of the study
One limitation of our study is the lack of radiographic confirmation of pneumonia and microbiological confirmation of the infectious etiology in some cases. We will be able to diagnose malaria, based on rapid diagnostic tests; however, bacterial, viral, fungal and other parasitic organisms cannot be routinely identified. We may collect samples (nasal swabs) for viral diagnostics, and we may analyse stored samples for molecular diagnosis of pneumococcus, if resources permit. Additional laboratory testing such as blood culture, sputum culture, viral studies, and a panel of infectious diseases serology would be necessary to definitively diagnose conditions like pneumococcal pneumonia, viral respiratory tract infections, and Mycoplasma infection. However, resource limitations preclude an exhaustive battery of diagnostic ___________________________________________________________________ Version 3: 15 Oct, 2013 16 tests in our setting and others. Although precise microbiological etiology may not be known, length of stay (primary outcome) as well as mortality (secondary outcome) are clinically meaningful outcomes that can be assessed unambiguously in the context of our study. This study will allow us to demonstrate the non-inferiority of SPO2 for treatment of hypoxic respiratory illness, irrespective of etiology.
ETHICAL CONSIDERATIONS
Risks related to the study Oxygen therapy is known to be a life-saving intervention, and this study will improve hospital capacity for the treatment of hypoxemic children. While patients will be randomized to one of two possible oxygen delivery systems, there are no risks, and potentially life-saving benefits to receiving oxygen, regardless of delivery modality.
One minimal risk associated with the study relates to drawing blood samples, which will be of low volume and will be collected by experienced practitioners. There is no risk of anemia related to removal of such a small volume of blood. The risk of infection will be minimized by careful decontamination of the puncture site using alcohol. Pain may be minimized using topical anesthetic, according to the practitioner's judgment.
Study participants will be managed at the Jinja Regional Referral Hospital according to national guidelines and local clinical practices. Outcomes assessed in the study will not pose any risk to the study participants (abstracted from the chart record).
Institutional Review Board
The Makerere University (School of Biomedical Sciences) Research and Ethics Committee (SBS-REC), together with the Institutional Review Board (IRB) of the University of Toronto will review this protocol. The Uganda National Council of Science and Technology (UNCST) will also review the study.
No deviation from, or changes to the protocol will be made without prior review and documented approval/favorable opinion from the IRB/independent or institutional ethics committee (IEC) of an amendment, except where necessary to eliminate an immediate hazard(s) to participants, or when the change(s) involve(s) only logistical or administrative aspects of the study (eg, change of monitor(s), change of telephone numbers).
___________________________________________________________________
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Subject Confidentiality
Study participant information will be kept strictly confidential. Study data will be accessible only to study personnel. Study data will be stored long-term in files and computer databases in locked offices. Access to databases will be passwordrestricted, and network security measures will be in place to ensure that information cannot be retrieved by personnel not involved with the study. The study monitor or other authorized representatives may inspect all documents and records required to be maintained by the PI, and the study site will permit access to such records.
Potential benefits of the proposed research to study participants and others: Current practices at Jinja Regional Referral Hospital for oxygen delivery involve the use of oxygen based on clinical judgment (without the routine use of pulse oximetry).
Oxygen concentrators may not be in good repair, or the electrical supply may be inconsistent. Oxygen masks and nasal prongs are available, but of inconsistent quality. This study will substantially improve the care that patients receive with respect to oxygen therapy, with quality-assured devices, well-maintained, consistent power and quality equipment (masks, nasal prongs). Thus participants with hypoxemia will benefit directly from participating in the study with improved delivery of a potentially life-saving therapy. Furthermore, we hope that this study may be an impetus for increased research, which is a potential long-term benefit of the study to the community. If this study documents the clinical utility of SPO2, this would represent an important finding with the potential to accelerate development of clinical tools to promote child survival through improved oxygen therapy across the country and globally.
Consent
Informed consent will be obtained from the caregivers of all children that will participate in the study. The consent process shall be initiated at the time of enrolment into the study and shall continue throughout the child's participation. The consent will be done in the language that the caregiver best understands. If the caregiver provides consent for study participation, the caregiver will be given the consent forms to sign. A copy of the consent form will be given to the caregiver to keep while a duplicate copy will be kept in the patient's file
For those who do not know how to read and write, an independent witness will be present during the informed consent process and will sign the consent form as a witness. The caregivers may withdraw consent at any time throughout the course of the study, and this will be made clear in the informed consent process. All individuals will be informed that there is no requirement to join the study and that standard medical care will remain the same regardless of study enrollment.
___________________________________________________________________
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If the caregiver chooses not to have their child participate in the study, the case will be turned over to the clinical team on duty for routine care of their condition.
UTILITY OF THE STUDY
New ways to deliver oxygen for children with pneumonia in Africa could improve outcomes and save numerous lives. If this study documents the non-inferiority of SPO2 relative to standard oxygen delivery, this novel method of providing life-saving oxygen could be rolled out across centres in sub-Saharan Africa where oxygen cylinders are not widely available and electrical power is not reliable. Our study incorporates a plan for expansion of the SPO2 systems to several sentinel sites across Uganda, with surveillance for pneumonia mortality that could demonstrate a mortality benefit of SPO2 systems. The potential energy efficiency, low cost and ease of use make solar power an attractive avenue of investigation for use in resource-constrained settings. Proof-of-concept that the sun can be used to drive oxygen delivery could stimulate commercial interest in this technology. The SPO2 system could thus achieve rapid penetration into the most remote or rural settings in sub-Saharan Africa.
CAPACITY BUILDING
This project will build capacity for clinical care of children with pneumonia at Jinja Regional Referral Hospital, Kambuga Hospital, and other sentinel surveillance sites across Uganda. Oxygen therapy is a basic and life-saving intervention that remains sub-optimal in many resource-poor settings. This project will build local capacity for quality assured oxygen delivery. Furthermore, we hope to build capacity for research and innovation at Jinja Hospital and Makerere University. Four study nurses, additional support nursing staff, and two medical officers will be trained in good clinical practices, research methodology and data management. Training will provide added skills including use and maintenance of oxygen concentrators, pulse oximetry, RDT for malaria and point-of-care lactate measurement. Equipment (e.g., Lactate Scout point-of-care instrument for lactate measurement) will remain at Jinja Hospital after the conclusion of the study, providing a valuable tool for improved laboratory diagnostics and patient care. With respect to laboratory skills, a Masters or PhD student may be able to learn ELISA techniques for testing samples in our study, depending on available funding. A Masters or PhD student could also gain skills in clinical epidemiology, by assisting with the data analysis and write-up of this study. Finally, participation in the study design, implementation, analysis and ___________________________________________________________________ 
APPENDIX 1: EXPERTISE OF THE COLLABORATIVE RESEARCH GROUP
Our collaborative research group is ideally suited to conduct the research study proposed. Our team is currently conducting a randomized controlled trial of nitric oxide and a prospective study of hospitalized febrile children in Jinja, Uganda. Robert Opoka (Ugandan PI of this study) has published numerous reports on the management of febrile children and malaria specifically in Uganda [37] [38] [39] [40] [41] [42] [43] . Michael
Hawkes (PI, Canada) has field experience with clinical trials in Uganda and has coauthored numerous studies of host biomarkers in sepsis and malaria 26, 27, 36, 43, 44 .
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